Universität Wien FIND

Due to the COVID-19 pandemic, changes to courses and exams may be necessary at short notice (e.g. cancellation of on-site teaching and conversion to online exams). Register for courses/exams via u:space, find out about the current status on u:find and on the moodle learning platform.

Further information about on-site teaching and access tests can be found at https://studieren.univie.ac.at/en/info.

Warning! The directory is not yet complete and will be amended until the beginning of the term.

301907 VO Development of novel cancer immunotherapies (2020W)

from target identification through target validation to clinical trials

3.00 ECTS (2.00 SWS), SPL 30 - Biologie

Registration/Deregistration

Note: The time of your registration within the registration period has no effect on the allocation of places (no first come, first served).

Details

Language: English

Examination dates

Lecturers

Classes (iCal) - next class is marked with N

- hybride Lehre -
jeweils 09.00 - 11.00 Uhr
Teil I: 9.,16., 23. und 30. November 2020
Teil II: Vertiefende Vorlesung zu ausgewähltem Immuntherapien
7.12., 14.12., 11.1. und 18.1.2021

Monday 09.11. 09:00 - 11:00 Digital
Monday 16.11. 09:00 - 11:00 Digital
Monday 23.11. 09:00 - 11:00 Digital
Monday 30.11. 09:00 - 11:00 Digital
Monday 07.12. 09:00 - 11:00 Digital
Monday 14.12. 09:00 - 11:00 Digital
Monday 11.01. 09:00 - 11:00 Digital
Monday 18.01. 09:00 - 11:00 Digital

Information

Aims, contents and method of the course

Currently, promising results are being achieved in the field of cancer immunotherapy. However, not every patients is responding to the available therapies. The lecture will:
(1) give an overview on current therapies: their potential, their risks and where they currently fail: description of different therapy modalities: Antibodies (check point inhibitors, protacs, T cell engagers , neutralizing Antibodies) and small molecule therapies (inhibitors and agonists)
(2) description on how cancer imrnunotherapy targets are being discovered: available methods for target screening and how to validate them
(3) description how to validate the targets
(4) explain why biomarker research is important for the success oftherapies
(5) describe the different stages of clinical trials

Assessment and permitted materials

written exam

Minimum requirements and assessment criteria

100-87%: Sehr Gut ( I ); 87,99-75%: Gut (2); 74,99-62%: Befriedigend (3); 6 I ,99-50%: Genügend (4); < 50%: Nicht Genügend (5)

Examination topics

Reading list


Association in the course directory

MMB IV-2,MMB W-2, MMEI II-3.2,MMEI III, WZB

Last modified: We 21.04.2021 11:27